Table 3 Stratified analysis of blood loss in relation to augmentation with synthetic oxytocin
Birth seat group | Control group | |||||
|---|---|---|---|---|---|---|
No oxytocin initiated | Oxytocin initiated | OR (95% CI) | No oxytocin initiated | Oxytocin initiated | OR (95% CI) | |
during first stage | during first stage | for oxytocin during | during first stage | during first stage | for oxytocin during | |
Blood loss | n (%) | n (%) | first stage | n (%) | n (%) | first stage |
<499 ml | 63 (38cif.6) | 23 (25.5) | 1.0 Ref. | 193 (56.4) | 162 (45.5) | 1.0 Ref. |
500-999 ml | 79 (48.6) | 49 (54.5) | 1.7 (0.9-3.1) | 113 (33.0) | 133 (37.0) | 1.4 (1.0 -1.9)** |
>1000 ml | 21 (12.8) | 18 (20.0) | 2.3 (1.1-5.1)* | 36 (10.6) | 60 (17.5) | 2.0 (1.2-3.1)** |
No oxytocin initiated | Oxytocin given | OR (95% CI) | No oxytocin given | Oxytocin given | OR (95% CI) | |
during second stage | during second stage | for oxytocin during | during second stage | during second stage | for oxytocin during | |
Blood loss | n (%) | n (%) | second stage | n (%) | n (%) | second stage |
<499 ml | 51 (40.0) | 12 (33.4) | 1.0 Ref. | 120 (59.0) | 73 (52.1) | 1.0 Ref. |
500-999 | 59 (46.5) | 20 (55.6) | 1.5 (0.6-3.2) | 62 (31.0) | 51 (36.4) | 1.4 (0.8-2.2) |
>1000 | 17 (13.5) | 4 (11.0) | 1.0 (0.3-3.5) | 20 (10.0) | 16 (11.5) | 1.3 (0.6-2.7) |